Remimazolam Besylate in Sedation of Postcardioperative Patients
Status:
RECRUITING
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
Intensive care medicine is vital in managing patients after cardiac surgery with endotracheal intubationin order to provide extensive monitoring to assure clinical stabilization. During this time of recovery, sedation is frequently employed. However, prolonged sedation risks negative sequelae.At present,propofol, benzodiazepines, and dexmedetomidine are typical drugs used for sedation of patients in intensive care unit.Each has its own advantages and disadvantages.The investigators try to find near-ideal agents for sedation,characterized by good sedative effect,minimal adverse effects and rapid awakening facilitating earlier extubation.Remimazolam appeared to be an effective and safe sedative for short term sedation. Study participants were predicated on age (\> 18 years), admission following cardiac surgery, still mechanical ventilation within 48 hours,and prior informed consent.Participants were randomized to receive remimazolam besylate or propofol in a 1:1 ratio for sedation with a target sedation depth before extubation.Finallythe investigators will compare the sedation effect and safety between the 2 groups to prove if remimazolam is appropriate for sedation in patients after cardiac surgery in intensive care unit.